Skip to navigation Skip to content

Clinical Trial: Siponimod (BAF312, Novartis Pharmaceuticals, AG)

Share

Details
Type of MS: SPMS
Treatment mode of action: To affect immune function
Number of Subjects: 1530
Medication: Siponimod
Location: Alabama|Arizona|California|Colorado|Connecticut|Delaware|District of Columbia|Florida|Illinois|Kansas|Kentucky|Maryland|Massachusetts|Michigan|Minnesota|Nevada|New Hampshire|New Jersey|New Mexico|New York|North Carolina|Ohio|Oklahoma|Oregon|Pennsylvania|Rhode Island|Tennessee|Texas|Vermont|Virginia|Washington|Wisconsin
Institutions:

Multicenter, worldwide

Contact Information
1-888-669-6682

Funding:

Novartis Pharmaceuticals AG

Description

A multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluating the effectiveness and safety of siponimod (BAF312) in people with secondary progressive multiple sclerosis.

Share